






© Ku l dlp Gr ewal , B. Sc . (H o n s . )
. ~ t hes is ' '8~bmi tted i e.'"the Sch ool of G; a du ate
. . . ' ~S t~~l es in p ar't:ia,l fulfill.ment o f t~e ~.
r e qul r eme nts _'for the d~gre.e 9 £
Master .:,f sc ~ence .......... ' . -.. r I
T~icOlogy
Memor i a l un J.trerstt~ .o f Newfoundl"and
,Sep t embe r'" 19B?
.J
s t . Jo hn 's ' Newfound l and c. r
• i- - ~ : ~
.. . ,
Perllheion h a a been granted
to ",the National"'· Libra ry of
Canada . t o IIt e r o fil ... this
the ah a nd t o ' l e nd o r 's e l l
c opie s o f the ·ft'l m.
, J
L'autorhat ion a i t l! acc ord' .
It: f e , Bi b llot h lque nationale
d u Canada ~ de .ic r o f tI. Be
' c e t t e thltae e t d e pr e t er ' ou
d e vendee ,,~. ezelllpla1; e a du
fi h l . l
-,
The author (d OpYri gh t , owner) L'aut.eur ( ti tul a i r e) du droit .
h a l!l , ~r e8e _r v e d ot her d'll.ut eur) Be ' r ' e e r ve , I e.
~~~~~~~t i~:e rt~::: ~ :~~ . :~~r~, ,~~~~~·e ~e;.fU~~~~i~~;~
- e xe ens f v e exe ee e ee . from . i t "e ltt r a i t . de ce l le,,"c1 n e
.• ay · be p ri nt e d ,o r .o t fle r wh e doivent e tee i llp rimi s au ,
reprc;»duced '-wi th ou t " htlfjhe r autcement r e p r od u lte eane eo n
wrltte. penheiO~' ( , . ",r h et ,10' 'or:t."






We exam~ed myocardia; inj~ry fo~iowlng Doxorub1c~n US~ vre
analYsis with the Automat.~d H1t ach! Analyzer of ser um •
<I . ac t ivi ty chan g es o f en zyme s s pe c i f ic f or myo"caJ;',dlal tissue .
. ~ . .
s~agu,e-D awley r~ts wer e ...a~lnist,,!r.r.d e.ither s~line . ~ i 6 ,
or 9 mg I kg do s e s o f DOX:O~~'blcin by !i.nt r;'peri t ones ];" • . .
• - . , ' . r
·a t 48 hO~rs poab oox~rUbi.9in 1n J oc tion , , . i"'~rOaSi?" dru9 · ·' . " . :i
dosa~e r e s ul ted in iricr~~S~~g ' mi~Car~l 8'1 ;~i~S~9 " , :c;
. : . , ' . . .' - . .' ,'; :. ' ,c. r, :: . :'•• :" "
co ncen:t: r ati'on . 0iWlr dru~ as: pi,~asured bX ttlg~ , ~e~form:m;c.e
liq~id .chro\Oat.~hY. Thi~ su_gg·~'st.S -incr~ a~ln.'g.' '. ' , .(f(<':': ;< ,:_ ~. -:
"' Do~orubicin dOS~ag'e l eadg-t~ i:~~~S~d m~.ca~·~~if~9~e · , " ....: : '<~3
co hc en t!a t ionof dru~g and , ~ s .~sSOCiate~d. Wi.th .~i.S~U,e ~allia~e ;" ~ " - . ...
a nd ~el:a6e o f ;c a r di ac-spe Cific en~~es: .r .' -.~ :. ~'~
, i n j e c t i o n . Bloo d sampl es ' were col l ec t ed 8t, t i me s 0 ~nd "4 8.'
hours posttr e atment. The re was enLnceeaee in' s erum
crea tine kina!fe ( except t~e 9 mg/k& 'i'n~~t~d ' ra t s ).."" lactate
de h Yd:r;Oge nase ( LO)', ~~Clu.c:l.ing. · e I,e~a.tiOns . 0; LD . r·:~rd " ~~ .*: " ~ ' "
is?enzymes and as pa r t a t e. amlnotransf.er~se (-A~:r a~;tlvltfeB. . '
. (, ;
Serum CK is:oenz~ separat~on/ b~ : e~,ectr,Qphoresi'lO! ·rev.ea.le~ .
t he presence o f an addi tio~n~ ~, bar:td cathodic~: , i:o ,~K~ ; ' . • ':< '
f ollowi ng ad ministra tion o f 6 ,'and' 9 mg/kg d9ses of' the ", "
drug . 'creat~ne - k~~~~~ ' i~~~~zyine ~'na:I~si 9: ' o~ , n1i i~Chondr~.v. :
a l s o ~emonstrated _thl s ~~nd i n a . p~~ ,i.tion "c:orr~sJ?9~di'lQ' t J:'
. ' ' . ' - ,;, . ~ .'.
the,t. observed in the. drug-treate" anim~,ls .
. ,
~i .
e'e these tias~s' rn1t~chondr1al da mage resulted i n 't he c e r e ee e
o'f mitOChondrial CK. _ " .
, ,', / . -, ,z:--
~t a dru~. dose of 9 mg~g .. increa~ed seru.~l,aniV.'
aminotrans~erase (ALT) and LD 4 end LD 5 isoenzymes was '.
o~served sugg~st~ng he~atot,o)(ici ty, .
If ·'>
I n rats ~ ·24 hour , ucin~ specimens were analyzed f or various ..1
erccnearcea pat-arne ters with t he use o ,f the Automated
Iti tB?l;li t n a lYZer ; the~ i\stra-8 Autom ated, Ana iyzer and t he
' Q}e.m~.t:r.i~ 9 ' D.1pstick screen ~est . to detect evJ.,dence ,Of;
':- ~,e'~al' d~"Iage'. The O~lY abnormality ' not:e d was ~ decreased
" u~ineV~lc;p ,~i.t~ i ncre a sed do s e of 'the drug .
, I "
,' .: .I ~:" ~1}~-:·New. ~ Zeia~and' white rab~it mode l , ~e:~ rlemonsb,ated a
. . ' , s,~r~m " CJ( ':~B ' ac tivity gre,ater tnen five perce nt ~f tot{ l CK
~~-~a~l,ftt~l~. ' all , r~bbi te ' 48 ho~r.s subsequent . t o treat~ent
"', ', 1 .' "1'i t h iOmg/:kg no xor-ubfc .tn , The re was ne: such effe'c e in t he
". .:6 a. l',1 n..~ -t~eate~ co ntrols. Myoglobin was detected i n the
" ', .... ' . ' , ' .,' ' ~ ' . '
ser,:!m'"',e, h~urs ~ollowing a ,10 ' {'9/ k9 dO,s e using the Rapitex
- . " 'My'~'l "tiin ki t . The origin 'Of CK- MB was believed to be
~~a;di'li~: ' ~J6cle ; ' ~o*ever the ,so.u rce o f mY~lObin COUl~ have
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1 .1 . Geperal Introduction
o "Dox oru b i c i n ( Adriamycin) is a cytotoxic anthracycl!ne
. . ,
antibiotic isolated.in 19 67 by the 'Farmital ia a e ee ar c n
Laboratouy in 'Mi1an~ Italy from the soil fungus
. .
Streptomyces peucet;u's var . cae:-ius . It ..can arse be
chemical ly prepared ,f r"Da unorub i oi n (Vigevani and ,
W:i,. l liamson . 1980) . The Doxorubicin molecule i s an ana log of
Daunor u bicin ( Dauno mycin) and d 1ffers f r om 1.t only by ?n
a d di1:iona l hydroxyl g~oup at pos i tion 1 4 (F igure 1).
. - ' , ' , 'Structurally 'the DQXo r ubicin eoaecuie contains t he
j .. . • .
aminosugar da u nosam..ine l i nk ed via a glycl)sidic bond to t he
4t~ing anthracycl1ne struc~ure . oa u.#'r6bicin was ,lHs~o~ered
in 1957. I ts antit umor activity was de mo ns tra t e d in 19 63 by
DiMarco -( Wei s s et a l ':; · 19 8 6 ) : _AS a result~ t h e structura l .
Simllar~ty of~he two, .!.n i rna l stu dies wer~ i nitiated an~ i n /
1 9 6 8 the al)ti t umor e ffec tiveness of Doxorubicin was .
,~emonstra+?~ :rhe fJ. ; st ,c l i ni ca l tr~ al WI;lS cez-r-Led o.ut in
1 9 6 9 by Bon ado-Oba ' and cowo r kers who established its
. . '
s ubstan t ia l an t i t umor ac t ion in the tre atment o f ac ute and
chron~c ~ l e Ukemi as , iymphoma s , Ho d gkin ' s Di s e aS.B and
Ewi ng' S s arcoma (Wang et al , 197 1) . ,S t u d i e s i n the Un i t e d
states tle gan. s hort l y } f ter an d in 1974 the Food and Drug
Admin i;atratiori ap proved its us e. I t is a broad spectrum
,an t i neop l as t i c agen~,u8ed s uccesSfUl, lY s i ngly o r i n
. c o mbination chemot he rapy f o r a wi de var i : ty of
( ,
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malignancies . It is ~he mos t active single ag~t 'i n the
menagement of e ndometrial can~er in that it pr~du~s
objective r es pon s es i n 40% of -;.at :1Emt s . I t ~s the L o s t
effective single agent in metastatic preast cancer . I t
produce s r egression i n os t e o geni c and soft tissue · sarcomas.
Ch e mot he r a py comb inati ons u t ilizing Doxorubicin ha v e been
reported to produc e comp lete reepcnses i n lymPhomoas •and
, hematolog"ic maligna~Cies ( Po r t loc k and Gr~ff:i.net , 1 9 86). ~ .
The·.mechanism of '~ntitumor act:vity o f Doxorubicin i s
re lats? t o it~ ab~li~.Y to int?ract with epec:lfic s i t e; on
. DNA'.. preferably G:'C base pairs, v ia intercalati t;:lri' of the
' i .
anthracycl~ne ' r ing b~'tw_eenadjacent nuc leotide bases . This
resu l ts '~n steric Ob!ft~~ction and template disordering withf"
consequent inhib:Ltlon of the enzymes i rwol ve d 'i" DNA.
replica tion-DNA deperrdenti DNA po lymerase a nd
tran s cript:l:on-DNA dependent ·RNA pOlymer.ase (Blum a~d
'Ca r t e t"', 1974 ; Barranco, 1984) . Doxorubicin a lso i nhibits
\rotei~ s ,yntheS iS', The dryg ,is not ce l l cycle speci £ ic bu t
rather cell cycle active i n t ha t it ac ts at all stages of
t he cell c~Cle (Ba rranco, 1984') .
Ce l l culture syst.ems treated with Doxo r ub icin have
, demonstrated i~hibi t a on of v iral, ba cterial .Bn? mammalian
cel l DNf\.':dependent DNA ~lYrnerases and bact erial RNA
, ~ , r
po l y me r a s e s . A 5 pg/ml dos e of the drug i nhibits
/' ,<}' \" 6
'ic Or por at l on of trl t .1a t ed thymidine lnto DNA and uridine
into"RNA ( Mornpar le,. at a~ •• 1976) .
--. . "
The interac tion Of'opxo r Ub i c tn with DNA proyes both
91 0 9 1e and double st~and breaks which are not s e en with
PU;lf1ed DNA but '-onl; .with cell~ar DNA i ndica t i ng this may
, ~ ,.
bathe result o f t he action o f intrac e l l u lar e n zYT1!8s s uc h
I
as r e pa; r eoecnccreeeee or topoisomerases i n resp0'1SE! to
tOpo~oglcal perturbat1.~i n' omtstructure (ROIiIs andl
. Bradley , 1984 ).
. 'Th~ 's t ,an d.s r d do sage schedule of Doxorubicin when used as III
J s i ng l e a9;ot i s 60-75' ~g/square mlfterbY_lntraveno~s -~. ) ,
"i n j e c tio n onc~ Jva ry 3 to 4 we ek s . Tq"ere is sUbstantia, ~
p lasma protei n binding . perhaps appr oa ching fi fty percent .
Doxorublc~n exhibits first order type ¥netics i,n i t s ·
eU.mination from the p l a sma . It has a trlphasic p1Bsm~
dlsappeara~ce cur~ with approximat'e h\. lf~l1VeS ~f 10-30
minutes , 10 hours and 24-48 hours ( Young e t a1. , 1981) . .
. . .
Pharmacokinetic s tudies r ev e a l fai rly h igh concentrations





Whe'n admlnl~~red intravenously Doxorubicin is r ap i dly
c lear ed from the' blood and distributed to the t i s s ue s .
There ere vcaeer diff~rences ~n the apparel)t tissue-to-
paaama pa rtiti on coefficients (Kp) amorig tissues , but in
all cases this Kp value is unusually large . Th1. s drug binds
t o t h e DNA so i t i s postulated that t he -differences in .-
tissue distribution depend ~n tissue DN.8,. concentration
( Te r a s ak:L at a l . , 19B2 ; Terasakf' a t aI. , 19iU'h Terasaki
~ ~~~s~s other mech an1.sms s u c h as: ' a low e r ca pacity o f th e ,
~ to bind t~ t he DNA and/or t he e x ist e nce o f a barr:l,er
to i ts e n t r y i n t hf se tiss"u e s t hat exhibi.... a l ower Kp
va l ,ue ,
" The metabolism of J)oxorubicin i s similar to that of
uauoorutncan . The metabOlic path~ay is ';llust:.:ated in
Figure 2 . The ·primary meta~ite is' Adriamycinol"1'" t he C- 13
hydroxylation prod~c~ of the actton of NADPH-dependent
aldo-keto re~u'Ct: a5e , a cytoPla8m~c enzyme. ).1biqUit~US.lY
d~stributed in man . The ~aunosam1:ne moiety i s then cleaved
by m.icro som al gly cosidas as , present in, most ea eecee , to
ptoduce the inacti ve aglycones De0fi;adriamycinOl a~lYCOne·
and Adr iamycinol ag lycone which £e '~Ub SeqUen.t l Y
pemethylate.d to Demethyldeoxyadriamycinol ' aglyco~e . The
demethyla t ed met abolites are conjugated t o SUlfate and
g l u c u r on i de e s ters and e xc r e t e d ,
The predominant routEh. of 'e l i mi nat i on of the drug and its
,
l\le~abolite.s i s vii the ~ bile. Approximately 40-50t ~f . the
administered dose 1s .e x c r e t e d by ~his r oute over a period




a c counted f or by the pa r e n t ' d r Ug' AdrialllYCin~l accounts, ~ ,
f or 2 2 % and 3 9' is . a ttri b u ted to the r e:lla i ning me t abol i t es .
On l y 7 -10t o f 't he dose is' e liminated in the u r i n e over 5
d a ys; 40 ' as Adr l a my c i n. 29' a s Adrlamyc i no1 and 3U as
I " ,










F i gu r e 2 . Metabolic Pa:thwa y o f no xorubrc.tn an Humans .
He a vy ,a r r ows indica te pr e f e r r e d : prOduct~s . ·
1. Ad i~mycin \oxorubic ln)
, "' I II .
Add in0 1
Deoxyad r iatnycl n /
IV. Deoxy~rfaraycinol .
v. ~driart1yc lnol aglycone
VI . D!3methyldeox¥adriamycino l
VII .
VIII .
. Sulfate con j uga te













Adrlamycino l ha s t he ability to bind to t h e DNA and
t herefore i s thought 'to retain t h e t o xi c propertie s o f
Adr i amyc i n . Although t h e r e i s no di rect evidenc e , there are
o bservations which su gg e s t that Adrlamycino l ca n g en era t e
t h e p x o du ot.L c n of cytoto x i c s uperox ides ( Se e s eceacn
1. 5 . 1. ) . Also i ncreased myocardial l e vel s o f this
metabolite h a ve been de tected wi th t h e occurrence of
f un c t ion a'l and morphologica l c a r d i ac al te rat ions ( De l Tacos
at a!., 1 98 5).
' 1 . 2 . Acute T oxlc1ty
Mye i o sur'pr e s s lon is a d6 se.;.'de p e nd ent, dose l1 miti ?9
comp l ication in 60 -BOt o f patients . It is manifest
. pri ma r i ly as' a ne'utropen i8, re~chlng it~ n adir- 10-14 d ays '
f o llo wi ng t r eatment. Whit e blood ce l l counts as l ow as
1000/ c u mm s hou l d be expected . Thr omb ocyt o peni a and an emia
may a lso oc cur bu t ar e les s seve re . Care f u l hema tol 09i~
man ! toring o f WBC , RBC and platelets 1s ne c e s s ary in the
event t hat dose red uc tion or d e l ay of the rapy i s r equ i r ed .
Complete r ev e r s i b l e ' alopecia oc,cu rs in e r o s e t o 1 00% o f
pa tient s . Na u se a a n d vomi ting a re frequent s i de effe cts .
.St omatitis ma y oc cur 5 t o 1'0 days followi ng drug
a dmin i strat i on . Very ra re l y, f e ve r an d ,chi ll-s, ' urticari:'a ,
~. J ' \





i mmediate l y afte r injection . Qther s ide effects include




injection, . darkening of . the veins . ue e d for ad ministration
and hy pe ruri c emi a ( Be c k e r , 19B1).
Acute e lectrocardiographiC (ECG) changes . i nc l ud i ng
~~d:ycardla, ST-T wave changes, alteratl~n; ' in t he QRS
~O~pl~X and extras,ys.~Ol ic contractions are f r-equenb , The r e '
have be e n i nstances of Buddei'\" de a t h fOllow1ng ,t r e at me n t
~hich ha ve been attri bu ted to arrh y t hmias. However Fre i ss '
. and c~ke~s Question this. - A. stu dy g r ou p of 30 patie nts
who rece i ved 'Doxorub i cin i n combi nat iori with at,he r
c hemo therapeutic a ge n t s were . monitored by continuous , ECG
~ec6rd:1r\g de v i c e s 24 hours prior to treatm~nt and ,2 4 hour s
" :'dur i ng a nd following therapy. NinJt o f t he 30 p Jtients
experie~ced pretreatm~n't~ventrlcUlar ectopy wh1 ch':d id4 no t
/. i ncrease .r n s eve r ity po~ttre'atment . Th ey s~9geS~~
pret r eatme n t monit~dng t o r~l. e out ~iu.? t~erapy . as i t s
source (Frei~!l e t a1\ , 1 985 ) .
.D~XO:rubiCin7i~ ~ephroto~icity has been, repor~ed ,
f ollo w1n g only ,on e cos e of t he drug i n male Sp r ague -Da wley
.t:'~t~ , ' Bert a~i descri~'ed ne'Phrot~c al .t eratio ns a s ea:C1Y as 3
hou r s following t reatmen t a s ' a red uc tion i n gl~merular
_ 13
membrane polyanions. which i ncr e a s ed In ee ve xd t y with time
{ Ber~ani e t 81. . 19S2} .
The r e Is an apparent s e quen c e of pathological changes wi t h
r e s p e c t to the glomerulus . Firs.tly, there is. the earl y l o s s
. G ·
o f g l omerular membrane pol yanions . fo llowed by f us i on of .
(Gi rou x at . sl . , 1980) .
the f oot ' pr oc e s s e s , micro vi ll i formation and l imited
vecuoi re e tucn . Thi s l a t t e r change be co me s more~ d if f u s s , a nd. (
e ncomp a s s es disarrangement and s c l ero s i s of the~ufts { "
. ~
In'" addition t o the al ts,ra tions 1~ renal mO~~?l~ t~",re
" " also cha.nges i n bl~ c~emlst!"le~ i ndicat7v e .?f .
nephrotox icity. such as elevation of serum chc:leste'rol • •
triglycerides , tota l 1 1plds~ uric acid , creat1nlne and
. . '
. blood urea n1 trogen (BUN ).
" '. : .. , ', .. . . ' II,




:,;;. ~.Ph=t1C ~;ndromJ~t~uc~d Wi~h';"xorU~ioin ~S; .h.,... ,:... . r >:
been demo,nstrate.a in liIsoJeX;al,an1ma l speCies,\JlowQV~ i t.s ~:' --
: \ o¢~urre~ce ~~ m.~D rj'a s not :be e n c~n91S;ent'iyl~e~eed ~
oJ I Do"p.rUl:)!Ci n thDf'a~y was thoug ht t o be , r e s pon:ir;i; 'f o r ;Qe.~
.lJc¥ma g e '1n an e l derlY, man who was tre ated f or sq~amou; ce~
• ce r-cm oma o f the ,l U~9 SUbs ; q ;7ent to treatment withG,eomg \
. 0,£•t he \ drug ... Six ' we;ke sUbs e qu ent to the l ast d ; se r~na l
biops ; revea l ed .se~e i nterstiti a l fi brosi s and tubular
, a't l::llO~hY W~hl· ~ll~ ,g ~ O~erJul a~ ~·i {trat10~ . fu s ion and 10 98
. 14 ~ ,
las p rote i nuria and jlematuria (Burke 'et al., 19 7 7 ) .
'"of foot processe!j> and abundant microvi ll i formation. Th e r e
we r e increased se~levelS of creat inine and BUN as well
f
~rdio"toxiCi.,
.. - ; . .. . J
The '~velOPITl~~t ' of dose-depen~e~t cardlotoxiCi1;;Y wi t h
. ctrronLc administration ~f.Ooxorublcin limits its use in
,",O~cologic praetice. Gott lieb was t he fi rst to no t e t h a t'" at
cumu lative doses above 550 m9/squa~e meter t he i n c i denc e o f
mYOCard'ial d a mage 'was unacceptab~y h i g h a nd r~ended
ceeeat acn of drug therapy beIow. this: tota l dos e l e vel
. -. (Legha et a l. , 1982), Ho wever- pathoJ.ogical (c ha ng e s in t he
m'yoca :rdium hav e be e n de scr i bed iit )p a t l e n t s who receive ' as
\
li t t l e as laO mg/sq m and ha ve not b e e n repo rted in others
who r e c e i ve i n ~~SS \Of 1000 mg/s~'m . 'Ther~for~ the ,
c lJ.i'lic ian mus t decide wheth~ to cont inue drug a d mi nist"ra :'
t ion as a succes~ful anti t umor agent, concurrently ~isking
the development of card-botoxic i t y , or t o halt t h e r a py i n a
r e s ponding patient .
The cardiotoxiCity is common ly categorized' aS I elitr\er acute
whioh' i s man i fest p r imari ly 'a s electr o c a r di o g r ap h!c
t .
."
a l t era tio ns o r a s ch,ro n1.c c ardiomY,opa.t hy whic~ 'may deve lop
i ntQ c o ngest ive he a rt failUre ( cK( )\ .~




reeorve.. within a f ew days t o 2 months . The developm~nt o f
these ch a ng es i s no t a n i nd ication .t o halt t h e rapy . ' however
life threatening ven t r icul a r arrhythmias and deat h h a ve
\be e n report ed s ubs equent t o Doxorubic i n t reatment .
, -
An uncommon occur renc e i s the dt.v e1.op ment o f c a rdiomyopathy
~
a fte r on ly 2 courses of tre atment bu t t here i s minima l
funct iona l dete rior at i on.. un til a p atie nt- s pe c i fi c deg.ree of
d a mage i s exceeded prod uCi ng CHF. Cl1ni c ,l ly s ympt oma t i c
biventr~cU lar CHF us u a l ly deV~loPs wi t h i n a ,,:eek t o .2 . 5
.' mon ths a fte r t he l ast dose of Dp xorubi cin, howe ve r 'i t has
be e n r epor t ed to occu r as l ate as 7 yea rs fo l l owi ng the r a py
(F re ter e t aI. , 1986 ) . If t r e a t ed e arly i t lIIa y r e spond ·to
c a r d i ac 's u ppo r t •
. ... .
The mor t>ho logical features o f Doxo rubic in- i nduc ed car diac
. , .
t ox icity have ~een well ,def.1 P1ed~ i n lIIan an d seve r a l
an i mal models and c ha r ac ter i sti cal 1Y , i nClude v ac uo l i z at i on
~d a decrease in the ' numbe~ of myoc ytes , 1nte~st\tia.l
edema , di s tent ion o f the s a rcoplas mi c r e tic ulum and
s we l l i ng o f ' cardi~ ·;"i t oc hon dr i a . All Qt ' t h ese lesions . are
f oc al, for damagecL t1~su~ . can be f ound adj!"ce~t ~o norma l
t i s s ue, ho we ver with c ont r nuenc a . of the r apy they become
. d i s se1Jllnate tl. Manyef t he se hi s t ologic Cha,ng es are .tYP~Cal
o f cardi omyop athies o f ·o t he r o r igin s ( von " Hoff e t a l . ,
1982.; SaItle l a nd MCGui r E!. 1986 ) . ~hen r e po r t e d a neg~~lve
'-
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c o r re l a t ion between t he c~iniGOal and histologic signs of
t OX! Ci t y. o In 23 ,o f 69 patien,ts who exhibited c linica l signs
of t?xiclty fo l lowing t r e atme n t wi'th Doxorubicin o r
Da u n o r ub ic i n , onlY" 10 had hi s to logic fleidings i n support of
th1s. such as vecuo a t eeeron a-;"d my o f l brl 11 a r l o s s an d
interstitial .f.ibrosts . In,21 of 46 p a t ,t ent s who had no '
c linical signs there was h i. sta l ogi c a l c o n f i r ma t i o n of .
_ ""7- ~dlotox lc i t~( COh~n at ·a 1 . ;:i98 6 ) .
When a patient r~c~iv~n9 Doxorubicin c h e mo t h e r a py presents
with ,8 cardi~c disorder ' one
J
should suspect the d rUg as its
,c a u s e however t here may be other fac t ors r esponsib l e such
as tvmo.r involve men t ¥ .t he peri ca r d kim , infect~~
compl icationS' o f the r a p y , nonbacterial t hrombotic
endocarditis , nutriti ona.} deficiencies -.a.r:od compH. cations of '
therapy ~'l'okaz and Von Hoff'; 1964 ) . TheECG 8 lter';lt1ons
occur in anywhere u p to 41t of. patients . However many
cancer pafte"nts, are . f e l#f.U e , weak and ma l~ourished wh ich
~ may-~ c~ntribu~ing. factors . · .several risk .f a c t ors h a v e been
~ .... . .
identifi ed f or the d e velopme nt of cardiomyopathy. They a re : .
1 ) AGE ' \Th o s.e 70 years of a~e .o r gre a f e r a n d t he group more
recent ly identi fi ed, young c hi ldren, a r e t hought to b e a t
. ' I
g r e a t e r risk. 2) -MED;1AST INAL IRRADI ATI ON. Pri or or
concurren t media st!"n al r adiati on part i cularly t o the h e a r t
i s as..-sc..ciated wi t h a n i ncre a s e d r i sk o f development o f




association between pre-treatment cardiac d isease and
hypertension and a greater incidence of cardl0m::r:-~pathY
development has been documentedhy several a uthors. 4 ) -.J
nOS ING SCHEDULE. The usual dosage reQimen is once every 3
weeks but a W~lY schedu~e is associs:ed with less
cardiotoxic!ty. 5) OTHER DRUGSb. I n studies of patients
receiving' mUlti-drug chemotherapy containing
c yclophosphamide and Doxorubicin a more toxic r.:esponse
developed than In those receiving only Doxorubicin . 6)
TOTAL DOSE. The mast important risk factor as described
earlier .
1.5. He~})anisms of Cardi~tox~city
1 . 5 . 1 . Fre e Radical Theory
In spite of extensive investigations the mechanism of
cartliotoxic'ity produced with Doxorubicin use is' 'not known .
. . . '
""any theories have been forwarded which inclu4e excess
" ' , "
calcium influx, disruption of t he e lectron transport chain
in myocardial mit~chondria (Johnson et a l ., 1986),
inter,act~on- wi th SH-group~ containing enzymes (Fabr~gat et
al ., 1984), alteration o f the membra ne-bound Na - K - ATPa s e
pump ~Gosa lve z ee a t . ', 1979 ~ , direc't e ,ffect o n the cell:
membr-ane (Murphree at a1., 198 1), r ea e e e e of histamine and
. catechol a~ines · ( Jac kson ~t aI ',. 1 9 ~4 ), arid the gener ati6n
. -/"
of Doxorubicin-induced semiqul~one f r e e rS dic;st an d
";1
1.
subsequent oxygen-der ived , epee.tee which c a n d isrupt
intracellular membrane sys tems , result -rn ,l i P i d:
peroxi d a t i on o r reac;: . wi t h DNA and / or othe r macromolecule s .
( Be r lin and Hasel tine , 19 81 ; Halliwell and Gutteridge ,
1 98 6 ) .
I t h a s been wel l documented t hat the one- e l ectron r eductio n
Tl
o f Doxorubicin t o the unstable ye t activ.e semiquinone f r e e
radical i nt~rm.edi a te is C~lYZed by mi crosomal an d nUCl j f r
, NADPH cytochrome P-4S0 reductase , by the t r a ns f e r o f
. e lectrons from NADPH to t he qu inone moiety of Dox0.rhbicin .-
Bachur . suggests t~t is t~e semiquinono free radica1G. 4.
whi cl1 intercalates into _the DNA t o induce strand ecteetoo
(B~rlin and Ha.s e l t i ne . · 198 1 ) . ho weve r t here i s mo r e /'
evreence i n s u p po r t of ,the theory t ha t under aerobic
cond i tions au toxidation of the semiquino~e generates ...
e upexcxd.de fre e radical (0; ) format ion " Dismutation of the
s uperoxide r a d i c al species produces hy droge n peroxide
("2°2) wh i c h i n t u r n can r eact with· the Doxorubicin
semiquinone i nte r me d i a t e t o ' produce the hy droxyl fre e
r a d i c al ( OM·' ), the most reactive of a l l these species. Th e
physiological c6nsequences of the formatio~ o f these act,.ive
• I
oxygen spscres i nclude DNA atr-and scission / and lipf"d
, '




Malondialdehyde 1s a toxic by-product of the degradation of
lipid peroxides . 1'1.0 increase in its content in the hearts
of anlma~s treated wi th the .drug would lend add! tional
auppor t; to the free radical theory . However ther~ are
conflicting reports as ,t o its production . In an acute model
,
of cardiotoxici,ty by Jackson, male New Zealand whlte
' . .rabbits were administeted an intravenous injection of 10
r ..'
mg/kg Doxorubicin. In this study there was..no difference in
malondialdehyde 'prOduction between ,t he control a nd
experimental groups (Jackson at al ., 1984) . On the other
hand Myers reported 1.ts pt<;>ductlon fO).lowing a 15 mg/kg
dose by intraperitoneal ( i .p.) i n j e c t i o n (Myers at ,ai. .
1977~.
. '
If free radical. production i~ wnol.l.y or in part responBibl~
for mYOCardia~....toxiCity, free. radical-scavenger agents must
, confer some degree of cardi9protection . .In ,mi c e treated
with the f:ee n v,ucal. scevenqee al.pha tocopherol 24 ho~re: .j
prior to drug treatment cardlotoxicity was significantly
r-educed as determined by e l.ectron microscopiC examination.
A l e t ha l dose ~?~ .85% of the anl~ale was subsequentl.y
reduced to a lethal dose for 10% with al.pha-tocopherol
treatment (Myers at aI., 1977).
The cell jies various intracellular defenses to protect
itself aga'i.nst the m1.nute quantities of oxygen radical
",'
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epeerea thijt ,are nor mally produced. Sup~ox1de d lsmutase
(SOD) removes ~. catalase removes H~O~ and g lutath10ne
peroxidase a nd g lutathione -S - t ransferase r -emov e hydrogen
peroxide a nd(iPidtpe roxides ( Hal liwell a nd Gu t teridge ,
· 1986 ) . The reduction of Doxorubicin to the free r adi c al
m~tabOl1te is ~reater in t he l iV~; than i n t he hea~t but
only the ~art eeveroce clinically S~gnificap.t .... '
morPhologi~8 1 changes . Why i s t h i s ? uorosbow demonstra~d
tha t ceee r ese activity i n mouse liver was 173 .3 ±. 10 .'-5 U
whilst ca rdiac catalase was 1.1 ±. 0.4 U « 0 .6% o f t hat in
the l i v e r ) .' AS we l l , t he ac tivi ty o f SOD in ,t:he -he art was
_~7.ol-% ' of th.lilt in t he live r . , An acu:: dep r e s s i on i n
glut~th ione pe,r oxidas e activity ,f o r ;~ours f ollowi n g a
s ing le -ecs e- of 15 mg/ kg Do~orubicin was e r ec observed.
There f o r'e Doxor ub i c i n .t::,.ay Potent i ate its own tO,xicity
(Doroshow et aL J 1980) .
1 .5 . 2 . Cel l Membrane Theory
The convent ional theory that Doxorubicin h~d t~ enter the
cell i n order to produce its t oxic ~ffect i s no w being
Chal l:n~ed" , Cytof1uorescence studies de monstrate t hat the
drug is localized i n the nu cleu s an d t hat i t intercalat~s
"'\ int o the DNA. Hpwever the cu rrent t hesis i :, that t he drug
may produce its cytotox'ic e ffects as ...~ r esult of ~





- o f e v i de nc e. 1n su ppo r t of t h i s. Firstly, active synthetic
s.nthracy clinas such a s N- t r i f l uor o ace t y l adr i amyc i n- 14
v alerate, an analog of Dox orubicin , has no , de mo n s t r a b l e
a b i li ty t o t:r.rftd t o DNA. For man y anthrac 7cllne de rivatives
synthesized 1n the l aboratory there i s no c o rrelation
between i nhibltic n of nucleic aci d s y n t hes is and )~
cytotoxic! ty0'~o detai l ed stUdl~S have ·shown t~at
Doxo r ubicin can e f f ect alterat ions in such prop er t i e s o f
the cel ~ membrane as t he expreSSi ~n o f hormone xeceptiors ,
transport o f s ma l l i ons a n d mole cu les , phospholipid
at.ruc ture and o rganization, fus i on properties and fl uidity
( Sie gfried a t a l., 1983 ; Trlt~on a nd vee , 1982 ) .
'\ . .....
Tritton and Yee prod uc ed a model wh i ch d emo nstr a te.d t hat
t h er d rug does n o t have t o e n ter ,t h e celh to be active . Th ey
, e xposed murine c an.cer cell l ines to large insoluble
polyme ric agarose beads t o which DOKor~bicin was co v a l e n t ly
attached. Th e c e lls were "e x po e ed t o the f ree drug ; the drug
a t tiached to t he s up por t (be ads) ' a nd the aga rose -'beads
themse l ves . The free a n d illU'llohilized drug r educed cell
s urv iva l while the beads had n o ef f ect. Th e intracellular
. . .
contents of thet c e l l were ex amined by h i gh performance
l i qui d ch~omatography (HPL C) t o s ho w that n ox o c u b r cdn was
not being r eleased from the s u p po r t polyiner .




cells without pro du c i ng ce l l l y si s . With conc e ntr a t i ons
below 10 0 }.lM_ i t c a n al tar the .d i s ca c y t e to achi oocyt e
. mo rphology p r o bably as a r eaul t o f A~P de pletion or c a lc i um
load i n g ( Hickma n a t al . , 1985) .
r -,
poxor u b icin h a s a h igh aff inity r or- ~ !l~l1Pl n.
negat ~vely char.ged p hosp ho llpitl specific t o the i n n e r
mt tochondfla l membrane . Severa l o f the enz ymes of t he
respiratory c h a in . r e q u i r e c a r d io l ipin for full a c tivi ty .
Ce l l c ul t u r e stud ies ,with myo cardial c e lls deindtJ.s1;~ate tha t
t h e r hy t hmic con trac t ions o f th,e 08 .11s ce ase with drug .
~c t rea t me n t and "t h at thi s. i s due to t he lack ~, ATP. s yn t he si s
( Goo rni agh tigh and Ruys9c h,ae r t, ' 19 8 4 ) .
r
1 . 6 . Ca rdiac .Enzymes
1 .6.1 . Creatine Kinase
. .
crea t1: e kinase (AT~ c1-ea~ine N- p~osPhotran.sferase ; CK;. ECV
2.7 . 3 .2 ) i s a dimer ~posed of 2 s ub units with a mol ecula r
weight o f 50,OO~ d al tona eac h. I.t is 'pres e nt b o th i n 't he \.
c y top l asm and mito chondria'of primaril¥ me~abolically ~ ')
activ~ tissues such a s the heart , b rain 8;.nd skeletal ~
muscle . As s hown in Figure j the enzyms is i n v o l v e d in t~
regeneration of ATP ~ An e l eva t i o n in total CK a ctiv,f1ty i s
not, charac~rlsti c o f a spec i fic diseas e stll~~or it i s
observed in s uc h varied c onditions as myoCardl~l~
"
~ .., -". \
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infarction, a:~te psychotic reectaone and a seve-E!. fa ll.
There a r e 3 1soenzym'es of CK al l of wh i ·ch a r-e c o mpo s ed .o f
combinations of the .M#and B polypept i de subunits so n ame d
because t hey were isolated from s keleta l mu s c l e a nd the
brain respectively. The 1soenzymes are CK 1 (88 ); CK 2
(MB); and CK 3 (MM) which can b e separated
electrophoretical ly . Creol'ltine kinase 1 i s the fract:ion' that
mi g r a t e s most raP.idly towards the anode. CK 3 i s the
slowest migrating -f ract i ,on .a n d CK 2 i s 1nterme d ia::e.
Creatine kinase 1 is distributed primarily in t he b r a i n and
nervous system but i s a lso present i n ' t h e lung, t hyroid,
gastroint:estina~ tract and ,geni tou r inary system. Creat ine
<k i n a s e 2 'Le p redomi nant i n t he h e a r t wi th a sma~ l a mo u nt
i'1 .the genitourinary sy~tem. Creatine ~kinase - 3 is presen-t
mainly in s keleta l .musc le but is found in most t i s sue s .
Creatine kinas~-MB appearance 1n the serum 1s widely u s ea
as a biochemical ~arker for p.athclogical myocardial .·in:~ury.
Howeve~, elevated reve i s could be e xpected ,lith signi f icant
muscle necrosis as in t he muscular dystrophies and mu ltiple .
forms of myosi tis.
,
Fol lowing a n acute mycoaxdLa j infa r c tio n' CK- MB app'ear s i n
the ..serum, us u a.lly wit~in ~~8 ho urs, it peaks a t "2 4 hO*s •
and returns to n o r m{ll levels at 48-7 2 h o u r s . ' l t s a p pearance






















































with a "v e Lue greater than 5% indicative of myocardial
• • , . • 1\
damagf3; (L-ott and Stang , 19~a)~ Skeletal .muscle injury wlll
ca use both tota l CK and CK- MB elevati~m~owever. t he %CK-
MB fill rem,'n le~. th,n fJve percent . :' '- (" ~ -
In 196 4 Jacobs d,e~crlbed a fourth c~ -r eoeoeyme t ha t was
associated with t~ ml,tochond~la-.- -It ca~ be ;listingU~ev
rom the ther\.iSOe~zymes b y the fact t hat i t moves t owa r d s
the ca~hode u r 'l ng el~c'trophoresls at ~ B.at whil e t he '
o thers migrate t o wa r d s t he anode ( Hall at al ., ~979) . This
.,





.molecular weig,:t is similar -"to t ht: of t h e other lsoenzym~s
.ncwe ver it differs '1n a,mino acid composition, amlno-
terminal a mino acid, electrophoretic mobility and i n
certain immunological properties ( Lang a nd WUr'l:bUrg,~
1982) . . I
\ . j
\
1 . 6. 2 . Lactat e De hydrogena s e
,r
La c t a t e 4ehydrogenase (LD ; L -lacta~e:NAD o.J;tidoreduc tase; EC
1.·1.1.27.l.-JlSs a mOl ecul ~r weight o f 134 000 de ltona. This
z i n c - con t ai n i ng enzyme ca talyzes t he interconversion ' o f ......
py r uvate a n d L- lactate wi th the cof actor NAD" or NAD
(Figure 4 ) . Lactate d'ehYdrogena9~ plays an important r o l e














Figure 4; The Rea~tion ttaly;ed by Lactate ~ehydrogenase
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T h e enzyute i s predominan t In the cy~c:>pla9m o f the . heart ~ .
k i dney , l i ver . skeletal mu s cle an d red blood ce l l. s . As 8
res;-'lt of its ." i de dist r ibution, e~evated t o t al enzyme
l evel s are present In . a n y disease s t ates" such a s hypo x Ia.
a cute leukemias and hepat itis .
1
Th er e a re 5 .1.s oenz ymee o f LO, each o f whic h I s a t e t remer
c omposed of 2 types of subun i ts d9s 1g nat9d H and M for
h e ar t an d mus c le respect.ive~y . The s u bu ni t com~s1tions of
t .h e l soenzyme s ar e : LO ·l : HHHH: L D 2: H HHM: LD 3: HHMM; LD
4 :HMMM; and L D 5: MMMM.
The LD 1 and LO 2 fractions a re norma l ly pre s ent p rima r ily.
. . .
.i n tissues with ae robic me t aboll911 BUeJ'I as the h e art .
k i dne y and b rain . T i s s ue s such ~s the . live r and skel e tal
muscl e w1t~ priaa r ily ana~robic u tattKtUSJU have a la rge '
portion of LO 4 an d LO S. Lactate de hydrogenas& 3 is
distributed in . any Vssu es. for exam p le e n doc r i ne gl ands .
s p le en and l u ng_
,
a n acu te myo c ardi al i nf a r c tion . ther e i s 8 typ i c a l - fl i p ped R
LD . p9.ttern an .tlat OL D 1 i s greate r t h an LD 2 th~t appe,a r s
within 48 hou r s-tn c lo se t o 80 t of pa t ients . Thi e usua lly
r e t ur ns t o no rma l v a l ues w~ln· one we e k a l th~?h t ot a l LD .
~ Jn t he normal human~ se r um LD 2 °h as t he gre a test acti vity ./
"
f o l lowe d i n o rder by LD 1 , LD 3 . LD 4 and L D 5 . Following
30
activity remains e aevece e ,
1 .6 .3. Aspartate 'Ami not r a n s f e r a s e
Aspartate am1notransferase (AST) is a dlmer of 2 "identical
s u bun i ts . It i s present i n the cytop lasm of the liver ,
k i dn e y . myo c a r dium and s keletal musc le . This enzyme is
1nvo l v e d i n t h e transami nation of an amino group from the
donor -amino a cid- L- asp art at e ., t oo an accept or keto acid-
o xe roeo e ue te , The h e ar t .a n d skeleta l mus c l e are a r i C,,"
sour ce of .AS'J!, ~d conseq uen t l y serum AST is elevated ln
: ·myocarQlal I nf a r c t .1o n .
Changes 1n serum CK, LD and A~T activi ty are of value i n
t he diagnosis of my o c a rd i a l damage . Creat ine kinase rises
" f
r a pidly starting a t 4-6 hour s a nd reaching peak va l ues, a t
. · r . .
2 4 -36 h o ur s . By t his time AST levels are .increasing and
uS~Ua ~lY peaks at 2:' 3 days. to t e nds to r ise a l i t t l e l ate r
a nd pe aks a t 2-3 d ays bu t u~ua l ly remains elevated for u.p
to 14 day s .
1.6 . 4. Myoglobin
Myoglobin i s a mono meric h e me-c o nt aining -pr o t e i n tha t
trans po r t s oxygen i n mammalian mus cles . I t "i s f ound in
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f.1bers results In the release of myoglob,tn .int o the serum.
Thi/has been "='emons tra t ed fOllowi ng irifractl~n o f large
skeleta l muscles and cardiac mus cle.
1 . ~. Ob jectives
The a i m of investigation wi th t he N~w Zealand whI te r abbi t
was t o study acute enzyme changes subsequent to Doxorubi c i n
treatment . The e nz ymes of interest wererC K, LD and
my ogklb i n .
Detaile d mon1.taring of acute toxic! ty a s s ocia t ed wi th .
Doxorubic i n us e ,wa s possi ble 1n the Sprague:-Dawley r at.
Serum e n zyme a n d isoenzyme ch~nges particu larly t h o s e
indicative of ,my o c a rdi a l d a mag e were a nalyz ed . Detaile d
u rine analysis was us ed to monito r r enal inj u ry , if any •
. The c;o n c e n t r a t i on of t he p a r en t drug In t he m:iPc~rd1Ulll .
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2 . 1 . Ha t e r i als
Do'x o r ub i c i n - HCl was k indly provided by Adria L a bor a t o r i e s
of Ca na d a ( MisS1BsBug a ; Ont a r i o) . Dr . Kenneth K -. 'Cha n
. (De p art me nt of Pharmacy, un1VerSl~Y Bf Ca l i f o r n i a at Los
t og e l e s , Ca liforni a) k i ndly supplied the Oaunorublcl~
stan d ard for the HPLC work . The "male Sprague-Dawley 'r at s
( 46 2 - 52 5 g) wer e obt~ined f r om Can a d i a n Hybrid Farms , Nova
Scotia. Male New zealand 'Wh1.te 'rabbits ( 1, 85 - 2 . 50 kg) were
~
pur c h a s e d from Memorial Unlversi~y of Newfoundland's l o c a l
vivarium. Bot h species wer e h ous ed in the Anima l Car e
quart ers, Faculty Of Medlc~ne . ) where they were subject t o
ai t e l-ost i ng 1 2 hour 11ght/d~rkness cy c1es with c~ntrolled
hu mi f i ty .
Met h anol wa s purcha sed from J . T. Bake r Chemical Company ,
New Jersey. Ch,loro form was supplied by Fis har Scientific ,
New Jers ey . I s op r o p ano l ( p.::op a n- 2-.p l ) a nd est phosphoric
acid were obtained f rom Alltech Industr ies , I l linois . All
of these chemical s were used f or high performance l i qui d '







" . . '
. I
,~ .
' 2 . 2 . 1 . i'n vivo EXl;)erill1entati on with Sprague - Dawley Rats .
The rats we r e permitted free ecceae to f o od (Purina Mi ll s
Rat Chow It 5012, S t.Louis, Mo.) and water unt il
approxim?tely 12 h o ur s b e f o r e . treatmf)nt at which t ime they
were wi t hdra wn. Ethrane (Enf lurane; z -chrcrc- r , 1 ; 2-
t~lfluoroeth.y,t d~f_lUQrOmethyl. ether . Ohio Me dica l
Ane s theti cs , Quebec) was use? t o i n duce eoeseuee r.a .. Five
rat~ i n eachl 0"£.3 experiqlspta J. groups were administered by
i n t r aperi t one al (Lp.) injection either 3, 6 , o r 9 mg/kg
b o dy we ight Doxorubicin. Doxorubicin wAs reconstitute d in
0 .9% saline i mmedi ate l y p rior to adminis tration to t he
ani mal s. One set o f 5 c o n tro l rats we r e treated wi t h a n
equal v olume of saline v ia l.p. injection . Blood sarnp ],es
we r e collected by cardiac puncture . The rats were t he n
i ndivid ua lly placed i n "metabo lic ceqes " for 24 h our u r i ne
s~mple collection at Whic~ time foo d and wa t er we r e
r etur ned. Following urine cc t a ectton the animals were
r e t ur n e d t o thei 'r separate cages. At 48 hours t he same
proce dures for producing anes t he-::ia and blood COl. 1.9ct ion
we re followed . At this t i me the r et s .we r e sacrificed by air
inject io~into t he h ear t . Samples of the heart were taken
f o r measureme nt of Doxor u b icin and its rnetabo li.tes and for
CK i soenzyme ~analysis. Th '; tissues were ke pt on ,i c e until
tran sferr e d t o 4° C.
37
2.2 .i .'1. Serum Analysis
The blood eemc i e e we re centrifuged at 1000 rpm for 5
/ .
mi.nutes using an Adams sero-fuge c entri fuge (Clay Adams.
Ne w York) . 'Tn e ' s e r u m was separated and as~ayed for:
(1) creatine kinase (CK)
(i1) l acta t e dep.ydro~onase ( LD)
(111) al ka l ine p ho e ph e 't e e e
.
(tv) aspa rtate amlnotransfera:;;e (AS T, ~OT)
( v ) a lanine aminptrarlsferase (ALT , GPT)
Statisti cal Ana lysis
. .
Th-e Stu dent 's t -test was u s e d t o test statist i cal
Qo
significance between t he va l ues obtained for the t o t al
e nzyme activities in "t he ind ividual rat at a and 48 hours .
Th.ia statbti~al'- t e s t wa s e rec perf~rmed t o det.erml~e any
significant. difference between t h e 4 groups ;, the 3
exper:l;mental B..nd 1 control :gr ou p .
\
2.2.1. 1 . 1. CK I s oenzyme Analysis
The cK,....~enZymes were e lectrophoret lcally Beparate~ on
Su per s ep re poc re cellul osic membrane s ( Gelm an Sci e n ces .
Michigan) . The Gel man . CK I s o zyme U: V . R~agent Set (Product
. »
3.
No . 51914 . Ge l man Sciences , Mi c h i g an ) wa s u s e d to~ visua lize -
the CK isoenzymes.
ere"atine ki n as e cata.ly zeS t h e r e ac t i on between c r eat i ne
phosp h a te and AOP t o yield c r e a ti ne and ATP . Th e l at ter
product I s coupled t o giucose to p CoQuc e 91uc08e - 6-
p ho s p h a t e a n d ADP . The reaction between glucose -6 - phosp!'tate
an~ NADP I s catalyz~d by g l ucose-6 -pho sphate dehydrO~enase
y Ielding 6-phosphogluco n ate' and NADPH', NAOPH fl uoresces
when axe! t ed by UV light I n the 3 40 -375 ,run r ange . The
Intens~ty_ Of fluorescen~e i s .d i r e c 't l y proporti~na l t o
e nzyme a C"tivl ty .
CK , Mg2.
Creatine + . M'P
A'fl>.-+ g lucose
I Hexokinase
) Gl ucose - 6- p ho s p h a t e
+ AD P




Gl uc o s e -6-phosphate + NADP - . - - - ) 6 -phosphogluconat e
dehy dr og en ase
• NAD PH
1 . Soak a , Supe r s e pr e pn c ce s t r1p 1n ioo ml Hig h
Re s olu t i o n Buf fer for at l e a s t 1 0 lIIinutes .
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2 . Remove the strip from the buffer and blot o n an
ab sorbent pad .
3. Place s erum samples and ex isoenzyme c o n t r o l " serum
. ( Roch e DiagnoStics Systems , New Jersey . Item 3 7326) i n
individual we l l s ' o f the applic;ator block using












Th e s tr i p is t~en loa ded onto a b r19ge a~d placed into
an e lect rophoresis c h ambe r tilled with buffer .
Th e s amples are tranS'ferred onto the.,an?"
Connect power supply and e lectrophorese at 225 V , for
c?
Du :>':'109 -the l ast 5 niinutes of the r un a substrate
t ransfer str i p 1 s fl o a t ed in 1 ml of CK 'ISQzyme . U.V .
Reagent (Product No. 5 1914) on a" g~as.s slide .
At end of r u n a ~econd g lass t Il de is p~lled acr~s
the surface o~ t he first at a 4-50 ' angle to alt pe l al~ .
bubbles and remove excess substrate.
The s~pe-r Sepraphore !"embrane 1s laid fiat onto t he
substrate transfe ' st'i~.nd •• seccne 9 1aas slids is
pu l led ac ross to -r 'emove °a i r) bu.bbles . .
It i s then incubated a t 37° C \or 3D' minutes .
The t ransfer s t r ip and in~mbran;;) arOe separa~ed .
The me mbrane is dr1ed~ us 1ng a hair dryer at low





2 .2 . 1 .1.2 . L~ I.SOen:t~a~YSiS
'"The LD .isoen~ymes were separated by elec troPho;eSll'f' on
Super sepraPho~ranes (Ge lman Sciences . Michigan).
Visualization of ~~~_\soenzymes was based on {he reversible
reaction be1;:ween NADH and pyruvate to f orm-l:ltctate and NAD ,
which i s catalyzed by LD.
LD
L-lactate + NAD ----} pyruvate + NJl.DPH + H
PROCEDURE - -:; V
1. A Sepcaphoce III electrophoresis membcan: - (PCOdUC!' j .
62092) is soaked in 100 ml High Resolution -"BuHer
(Product- 'No. 51104) a t leas t, 10 minute·g.
i~ The membrane i s removed from the buffer and blott8d on
. .
an absorbent pad ,
3 . The serum sam ples and contro l are placed 1." individual
wells of the applicator block using capl 1 ~ary tubes .
4 . The membrane is loaded onto a bridge . and p laced in an
electrophoresis chamber fil1'7d wi thbuffer .
. S . The sam~les a re transferred onto ' t h e me.mbrana .
6 . The' po~er s upply i s connected and electrophores~s i s
conducted at 225. V for 20 minutes .
? During t he last 5 mi nut e s of the run a suillstrate
transfer strip i.e floated in 1 ml of the LD reagent on




" .. ; ...
8 . At t he end o f the r un a s econd glass .JIUde i s gent ly
. run across the surface o f t he first a\-- 8 45 ° an g le.
9 . The membrane is held ho rizontally '~nd l aid fl at onto
the substrate transfer strip . . A second g lass slide i s
pulled across the s u r f a c e o f the firs t at a 45° angle .
/
10 . Th i s i s incubated at 37"C f or 30 minutes . .
n . The transfer strip' ana; memb rane a re separated and t he /"
. I
membrane is pl a.ced i n a 5% Ac e t i c Acid bath f or 5
minut e s .
1 2 . Next i t i s p laced in a cool wa t e r' ba t h f o r 5 mi nu tes .
13 . Th~ me mbrane is d r ied betwe e n 2 absor bent pads f or
a p prox imate l y 1 ho u r .
,14 . The me mbr an e is v i .sually e xamined .
15 . The isoenzymes were quant itated o n t he Beckman Model
CDS-~~O Compu t i ng Densi tomete r a t 575 rna.
, .
2.2 . 1. 2 . Tiss ue Ana lys i s
2 . 2.1.2 . 1. Ti ssue Ext~act1on
Heart tissue samples were a na lyzed for llI?urement of
Doxorubicin a nd its metabol i t es by h i g h p e fo r man ce l iqui d
c hroma t ograph y .
~ . ' "
The metho d f o r t i s su e extraction wa s ,a modi fi cat i on o f .t ha t
o f Cummi ngs a nd cowo r ke rs ( Cummings e t a l . , 19 84 ) . The
tissu es were a llowed t o t haw at r oom tempe rat u r e .
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A.pprox i mate ly 1 .0 9 o f t issue wa s washed 1n 3 rol o f
b u ffe r e d 0 .9% NaCl and minced wi ttl dissectio n scissors . A
homoge nate wa s pro d uc,ed usi ng a -ren-a e c ecx tissue
h o mog eni zer ( Fi she r Scientific , Nl;lva Scotia) . To 1 rol of
homogenate wa s added 5 ro1 of ch l oroform/isopropanol " (2:1 )
mixture which was then vartexed for 1 mi nu te using a vortex
mlxer'( Fisher Scientif i c, Nova Scotia ), then c e n t ri fu g e d at
1000 r pm for 15 minutes using the CU-SOOO Centrifuge
(Beckman Instruments, Ontario) •.Th.i s produced 3 phases: an
upper aqueous ph a s e , a ml .d d le tissue p e l l e t and a low~r
o~gani c phas e . The uppe r p h as e was discarded by aspi ration .
Th e~~wer , ph as e was ret~d by a SPo1.r~tlon t hrough the
tis sue pellet and evap~Fated t o dryr.ess in an analytica l
evapor a \or a t 40°C a nd 25 ,nun pr essure n itro ge n . The dry
extracts were r ec on stitut ed .a.n 75 p I cif -methan ol , a known
amount o f Daunorubicin wa s added to the sample an~ injectef
on to the HPLC .
2 . 2 .1. 2 . 2. High Perfonna nc e LiqUid Ch r omatography
:J'he HPLC system consi~ted o f a mo de l 42 1 Con troller, Model ·
11 2 Sol vent De l ive r y ModUl e and a Model 340 o rga ni ze r
( BjFkman In strume nt s, ~alifornia ) fit ted wi th an
s ccncepoere 300 CI B co lumn 250 mm in length, an d a n
i n t e r nal diameter of 5 }1m. A 25 }II Hamil ton syringe
(Hamilt on , Nevad a) wa s used to inject the s a mp le i nto the
-'
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Altex 210 sample injector and ont o the co lumn .
Th9\Or gantc phase co n s ist ed o f 99 .85% is~propanOl 1n 85%
ph o sphoric a cid ( 0. 15 M) . I t wa s filtered through a
mi~ llpore fi l ter o f pore s i z e 0 .50 pm ( Ml1 11pore Corp . ,
Mas sachusettsr. The aqueous phase was 99.85% water in 85%
pho sphoric a cid (pH 7 .6) . The r atio of o r g a n i c to aq ueous
p hase was 2:1. Th is wa s f iltered through a mUlipare
fI lter of pore s i z e o f 4'5 pm. The solvent system-'was pumped
t~rOUgh the column at a ,flow. rate of 0:50 m~(min~te . ')
Th . p eaks were det~cted wi t h a Model 121 Gilson fluorometer
(Man de l Scientif.i;.c. Cnt'ario) ' f~ tted ' with fi1 ters spect'ac
for detection of Doxorubicin .
2 .2 . 1 :2 . 3 . Myo c ardi al ~al CK ~alysis
Rat hearts were homoge ni ze..,d with 1% Tr i ton x 100 i n 0 . 155 M '
z<C1 in Ten -Broeck tissue homogenizers . · A ratio of 0 .5 g
t issue to 2 m1 med ium was used . The resulting crude
\ homogenate.. was centri fuged at 4°C at 24 000 rpm for 15
mi nutes in the International Portable centlH,fuge . The ~
euperneeene was retained and u l tracentrifu~ed at 40 000 x 9
f or 5 minutes a t room temper ature in a Beckman L5-65
Ul tra(·entrifuge . The s upe r na t ant was ana lyzed fo r total CK




4 .2.1.2 .4 . Mitochondrial I solation
Ra t l i vers were r emoved fo r t he purpo s e of mi t o chonprial
iso l a tion . The tissues were rinsed wi th 3 0 101 of i ce c o l d
Prep a ration Med ium which consists o f O .~5 M s ucrose, 3 .4 10M
t r ia - Hel, p H 7 . 4 at 20 °C, 1 roM EGTA (ethy lene -g l y col - b ls -
"( am~noethYl) t et.r a - a c e t a t e ) . Th e medi um was decanted. The
live r s we r e finely minc ed wi t h scissors I n a no ther 30 lOl o f
m~dlum • .{lis medium was decanted . Th i s washing ~rocedure
wa s repeat ed on c e m.ore . A crude homogenate wa a p repared i n
a h~lnd -held Dounce homogenizer 'wh i c h was filled ' With me dium
for a total vo l ume of about 55 lIli ll i l1 t e rs. The reSul,ting
homogenate wa s p ou r ed into a ·2 50 101 con ica l flask o n i c e t o
which an additiona l 50 101 o f me di um. wa s added . Th e
homoge na t e wa s centrifuge d in a Sor v all Ul trac e nt ri fuge
(DuPo nt, New J ers ey) at 650 0 'rpm at 4° C f or 10 mi nutes .
The s up er n a tant was de ca nted int o c4-ean centri f ug e t ub es
""
an d centrifuged a t 25 000 r pm for 7 minutes . The
su p, r n a t;an t was d~c~nted . The pell~t was gently resuspended
wi t h a gla s p rod and then poo l e d. Eigh ty milliliters o f
Pr ep a r at i on medium was ad ded . Thi s was poured i nto 2
centrifuge tube s and c entrifuged a t 25 000 r pm fo r 7
minutes . Th e pe llets were resuBpend~d as before into 1
, "-
tube and centrifuged at 25 ~90 r pm for 7 min utes . The
pellet .~a9 gently resuspended and about 3 ml of medium was
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added . This solution was then f rozen and tha~ed severa l
times and then used for CK i s oenzyme analysis pu r pos e s .
)
2.2. 1.3. Urine Analys i s
The sodium and potassium con tent of t he urines wer e
measured on the Astra -a A.utomated Ana l yzer . The techni que
employed "ion selective erectrode" met ho do logy. T'ota l LD
activity was assayed on t he Hitachi Automa ted Analyze r. The
The Chemstrlp 9, D~pstlCk test was purchased from Boehringer
/ Mannhe im, uueeec . The osmolal!t?' o~ the sampl es was
determined using t he Al:Itomated Osmette 'p"!rchased f rom....
Boehringer Mannhelm. Que bec ;. The procedure f or ' assay o f
total Piotein is as f ollows: '
1. Labe l tubes as BLANK , STANDARD #1, STANDARD #2, an d
URINE TEST #1" 2 • •• e tc .
2 . Add 9 .0 ml 1.5% sulfosalicylic ac id to each tube .
3. Add 1. 0 nil ~ri"e t o the test samples .
4. Add 1 .0 ml of standard to standa;-d tubes and 1 .0 ml of
0.85% sal in: t o t he blank tube . Comnukcially ava ilab le .
control s tandards were used a nd a pp ropr iately diluted to
give ecautacne of O.~4 an d 0 .32 giL .
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absorbances fit 420 run against t he b l a n k .
5 . Al low to stand at room temperature 10 minutes a nd read
ConcentrationAqsorbance Test~LCULATION :
Absorbance Standard standard
= co ncentration oi\rotain in test fluid
/ principle: The protein is precipitated with SUlfosalicylic
acid and the turbidity is mea sured .
2',2.2 . i n vivo Experiment~tlon wi th Ne w Zealand White
Two groups of rabbIts were studied. The five animals I n the
experimental group were adminis.tered 10 mg/kg Doxorubicin
in saline by Lp . injection . The control group of 5 anima l.s
were treatod ',<lit h an equal ·volumq of saline by the same
route. At predetermined i nt e r va l s b lood samples were
col1ected from the marginal ear veins using a winged needle
infusion set . The samples were centrifuged at 1000 rpm for
5 mi nu t e s using an Adams eecc-eoce centrifuge (Clay Adams ,
.. N~w York). 'rtie separated serum was used fo r measurement of
the tota l activities of CK and ~ on the .n eecnr Automated
Analyzer>, The rema.i rdng serum was stared at 4 _80 C for
myog lobin assay and CK isoenzyme analysis.
> .
2 . :Z.2.1. Myoglobin As s ay




was u s ed t o demonstr a t e myogl ob i n in the serum . This a s say
1s base d on an immun ochemic al r e a cti on between myoglobin
a n d ant ibod l Gs t o myoglobin bound to p o l y s tyrene particle s
produci n g visible a gglutination .
1. The serum samp les a re trans fe r red f r om 40 C t o room
t emper a'tur e.
2 . Fifty p I s e r um ~nd 10 ~ l absorptio~ so l uti o n (conSis ting
o f an anti bo dy so l u t ion ) are place d on a zo ne on the
t es t p l a t e .
3 . Twenty fi¢'e pI of t he RapiTex Myoglobin s o l ution
(COnsistl~9 Of \POl ystyr e ne p article s wi th antif'0dles
sens iti ze d to my?globin) are a d ded to t h e seru~­
absorption sol ution mixturfl :
4. The plate i s s lowly rotated fo r 3 minu t es end e xamined
for ag g l ut i nation..
5. A.ggl uti na t ion imp lie s presence of myog l obin 1n s a mp l e.
Th e CK Laoenaymee were a na lyze d by t h e same method as used
to a nalyze the rat serum and quantitated a s a percentage of
t otal CK o n the Beckman Mod e l CDS-200 Computing
Densi tomet e r wi th the following set ting s :
I
4'




( b ) Peak Height ccourca for setting maximum pen deflect i on
for the mos 'b de nse f r a c t i o n scanned: " - "
( 0)~ Sensit ivi.ty c o n t r ol fo r selection of de l1mi't
sensitivity value in the automatic peak detection : "9
o' clock position " .
(d) ModNontro l : " f l u o r e s c enc e " .
(e)~ Leng t h for se~t1on o f c hart trace length :
. "no rma l " . ,
efl Slit Con t rol : s lit s ize of 0 .30 x 2 .0 mm (small).
( 9 ) To select t he .U l t e r wave l~mgth , the fi lter- whee l
S~OUld be set a t po s ition 5, W.
(h) When OPFsting i n t he er ocs-eeceoce mode, t he ' 1










3.1 . Expet:"lmen tation wi t h Sprague-Dawl~y Ra t s
3 . r . 1 . Ser um Ana l ysis •
3 .1.1. 1 . To t a"l Ep zym e Ac tivities .
. -/
The act i v i t i e s o f CK, LD , ALT, A.ST~d e r jce i rne
phosphatase were assayed at ' 0 and 48 h ou rs f o llowing
. .
treatment wi"t h one dose of saline or Doxorubicin . "Each line
in f igures 6- 21 r e p r e s e n t s the data obtained at O. and 48
hours posttreatment from one rat . Th.s Student's t -test was
. u s e d to test s tatistical s ignificance between t he ' value s
obtained in the individua l r a t at 0 and 48 hours . I f the
e e su i.c s were. denionst~ated to be significant ly ~di f fe ren:t at
the 0.05 level this {s I t.::dicated in the de e c r-Lp t Lo n
accompa1ii9 each figure . This s~atistlcal t est wa s al s o
performe'dJto de termine~ny signifi cant diffe rence between
the mean s o f the 4
i n c l u d e d f ol lowin
ups . The result". of thi s t est are








Figur e 6. Total CK Ac tiv i t y Fol lQ wl ng Sal.;ne Treatmen t . At
a hour t h e activities were h igh and wi de ly dlstrib~ted .




Tot al CK Ac ti v i ty ( UiL)
-/
Figur e 7 . To t a l CK Activ.1ty FOl l owing .3 mg /kg Doxorub1.cin .
Ther e wQs a statistic al ly si gn ifican t i nc r e a se 1n ac U .v i t y
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Figure 8 . To t a l CK Ac tivity Follo wi ng 6 mg!kg Do xo rubic i n ; '
Th.ere wa s a statistically significant diffe rence n ~he
means o f the va lu es obtaine d at 48 hours as comp;a d to
t hat at 0 hou r tp- ( 0 . 05)
\
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Fig u r e 9 . To t a1 CK Activity FOllo'wi ng 9 IlIq /~g Doxor ub i c i n .
A. sig ni f ica nt , decre a s e 1n CK actl:1 ty wa s . M t e d kt 4 8 -h o u r s







To t a l ex Ac tivity (U /L)
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Stat i s tica l Ana lysis o f CK Activity
Wi th respect t o CK tota l activity there was a difference in
the mean. 0 hour values between the saline-treated cont r ols
and those treated with the 3 mg/kg dose and also between
the control group and thos e administered 6 mg/kg . At 48
hou rs post ! njectiO!'l there waCS a significant difference
be tween the 3 mg/kg and 9 mgjkg groups and between the 6
and 9 mg/kg t r e at e d groups .
60
)
Figure 10 . Total LD Activity f o l l owi ng Saline rree e e en e ,
At 4& h our s a s cC?mpared to 0 hour t h r e e r ats sho wed a
ma r gina l decr ease a nd .t wo a marginal i nc r ease .
61
Tota l LD Activity ( U/L )
0 ~ <;; :;: 0. ;, ;;; ;;; " ~ " rc
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Figure 11. Total LD Activity Fo llo\oling 3 mg/kg ucso r u b t.ctn .
Fau; of five rats demonstrated an increase in act i vity\at
)48 ho.t;!lrs a s compared to a hour . The one rat which
" . ' / "
d emonstrated a decrease in activity had a very high a hour
va lue as comp are d t o the othe r s .
(
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Figur e 12. Tota l LD Ac tivity Following 6 lIIg / kg
Doxorubl~ln . A s tat lst .i c a lly s ign i f ica n t i n c r e a s e 1 n LD .
actlv i ty was noted at 48 hours (p .< 6.05).
· ~. "
65 .
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St a t i s tic a l Ana lysi s o f LD Ac tivity
At time 4'8 hours the means o f the s a l ine and 6 mg/kg
treated groups and t h e me:ns of t h o s a lin e and 9 mg/kg
treated groups were demonst;rated to be s t a t i s t i c a l l y







Figure 14 ... Tota l },5T Activity Fol l ow i ng S a line Trea tment .
The r ats demons tra te~ eithe r mi n i ma l change ~r a decr ease




























Figure 15 . Total . AST Activity Following 3 mg i'kg
Do xo r ubicin . All r ats demonstrated an increase .Ln activity
at 48 ho urs a s co mpare d to 0 h ou r .







Figure 16. To t a l- AST Activity Following 6 mg/kg
Doxorubicin. There was a statistically significant





To t al AST ",ctivi t y
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Figure 17 . Total AST Activity Following 9 mg/kg
Ooxorub .icin. All r ats demonstra.ted an i ncrease 1n a c tiv ity





To t a l AST Activit'! ( U/ L )








Statistical Analysis of AST Activity
A trend for an increased activity with Voxorub1cin treated





Figu r e 18. ~ot a l ALT a c t ivity Followi ng Saline Treatemen~'l
with one ex ception in which there wa s an i ncrease 1n J
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Figure 19 . To t al ALT 'ACt!Vi £Y FO+!o wi ? 9 '3 Il'Ig j kg ,
Doxorubicin . The r e was 'a' min i ma l deJrease .tn e c t,t vity a t
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\", Fi g ure -20 : To tal- ALT Ac t i v itY!OllO'Wing .6 mg/kg ' ..
.....t DOX~~~lCln. Wlt~ one ex¢e pf10 n there ~~s minl~~.;l . .l~ci'rease :
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Figure 21. Total ALT Act!l.vitY·F~llowlng 9 mg/ kg '
~ Doxorubici n , A statist ical ly significant i nc reas e i n (
'ac t l v r t y was demons t . :at 4B hour~ _~s compared to~ 0, ho ur'
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...:.NO statistic a lly s i g n i f i c an t . dif~Q7~nce was dQmOn8tr~ted
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~ F .i;gu~o 22. LD-l i\c tiv it:;{ ~ollowing Trea t me n t wi th Salin~.
3 ,. - 6 or 9 mg/ kg Dcxer-ub ioin , Not:e . the incr e a s ed activi t y
at 48 hour-e wi th ~ncr~aSin.g DOXO~UbiCin dose . The Qtt;?u r
val ue r epre s ent s t he me an ' o! values obtained f rom 1 4 ' r a ts .
Th~ 48 h~ur value 6£ each dose g roup represents t h"e mean of '
ve lues ~or 5 r.'~ts . · Th i s i s 80 wi th f igures 22 -26.
-'
9 mg/kg
---<)' · · 6 rngjkg
3 llI g/ kg
----<>' contro l
)
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Fi g u re 23 . LD-2 f\.p tiv·i."ty Following.Trea tment with Saline ,
3, 6 or .9 mg/k9. Do~~r.Ublcin. N~te the minimal increased



















. Figure 2.~ . LD-~ Activity' FOllOwi~g Tr Qs t men t ~ith ~ allnQ" .
.: 3 , 6 or 9 ing/ kg Doxor ubici n. ]I" s l g ni f l C? ant i~ease"was
. . ,.,," -. n o t-ed o nl y wi t h ~h~ 9 mj'/kg .(I.rug dose. ' I"
.'; s -~ 9' mll / kg
. 6 mg jkg
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LO:-3 Ac ti v ity ( U /L )

















Figure 25 . LD-4' Activity Fqllowlng Tr eatment wi t h Saline ,
3 , 6 or 9 mg/kg Doxor ubi c i n. A s i gnificant increase was
no t e d wi th 9 mg /kg onl y .
9 mg/kg
6 mg/kg
• 3 mq/ kg
~ c o n t r o l
. /
-~ ... ' ~
9 5
LO- 4 Activi t y ( U / L I
"
.. .. Ul Ol
"






., ' - _. ~ '.
• 6
-, ..:~ . " : .. ' .'
Figure 26. LD~5 Activity Follpwing Treatment with Saline ,
3, I) or ·9 mg / kg Ooxorub ic i n . A s ig ni f icant in crease was ,
no.t~d with 9 mg/k g do se , only .
9 IlIg/k g
~ ~ mg/k9
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Figur e 2 7. Ser um CK I soenzyme P a t t ern Fo l lowing Tr e a t me nt
With' 6 o~· 9 mg/Ii~' ·~OXO~UbiOiJ;l . Note' t he ~d~ l t 10nal b and
, .
. cat hod .i c to CK 3 8S" compaE ed t o t he saline 1.njected
controi s' wh.lch · de~on9trate~ t he·" cy to90li"c is~n~ymes CK
1 , CK 2 and CK 3 c o r r espOndi ng t o t he standards s e en at t he
bott om o! rephotC:groPh . ' ; h1S f our'th ~.nd w:'~l1e~ed ' t 9 .
r e pr e s e n t itochondr(al CK. To de llOnstrate tha t thi s wa s
i n deed s o . mitochc~mdria we re i s o l ate d and analyzed' as t o





cathod e( - )
100
add!tional band
CK 3 CK 2 CKI
anode( + )
Samples 2 to 5 were obtained f:r;:om rats administered the 9
mg/ kg dose of the drug. Sampl~s 6 to 8 were from r a t s
treated with 6 mg/kg.
\




3 ,"1.2 .1 . Tissue Me a sur e ment o f Doxorub i ci.n
3. 1 .2 . 1 . 1 . Stan ljard CUrves
Two"",standard cur v es wer e nec e ssar i l y ·co ns t r uct e d fo r
determination ·0 £ Doxorub i ci n concentration i n vari ous



























OOS Oil 015 0.20 02!i OJO 0J5
( Doxorubicin Concenlralicn(J.lg )
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Ta ble 1 . Doxoru bic i n COncentr a 't'io n 1 n Myocar.~luft'l .
I nc reasing drug dosage r e sulted 1n increasing myoc~rdlal
tissu·e concentratlo~ ·or Doxo~bicln . Th e va l ues reprflsent
the mean + S .D . from-S r ats . ',~
)Dose Admini s t ere d




Tissue Mean Do xorubic in
concent r ation
( og / g)
6 . 1 5 '1 1.39-
50 . 0 t 9 . 30






















... . Fig u re 3 1. Mi t ochon d ri a l C~ lSOen~yme Patt e rn . Note the
. _pre~ence o f 2 ban d s , one cc eresscnes t o CK-~ o f the '
stand a r d ( a t bo t tom of pic t ure ) . Th e seco nd was cathodi c t o
. .




























Table 2 . €omparlson of CK Total Activity 1n Mydc~rdlum of
Saline and 9 mg/kg Doxorubicin Treated Rats. The r ; was no .
difference in total CK activity in the 2 groupS"". Each value
represents the mean ± S .D . of fata obtained ,f r om 5' .r a t s .
to
"










4 5 3 00 1: 91 5
3 . 1.3. Urinalysi s
11 6




Tab t e 3 . Ur ine Chem istJ:ies Fo l l o wing Saline Tr e a t men t
...
Table 4 . Urine Che mi s t r i e s Fo l l o wi n g Treatment wi t h 3 ..g /kg ..
r.. Doxorubicin . Th ere was a d ecrease d urine vo l u me in the 3
·mg/k g treate d g r oup versus t h e salin e adm i n istere d c ontr81
g rou p .
.~





Dos Total Osmola l ity Na K Ll> Tota l l( mgjk ) Volume , (Unit) ( mmol/L) (U /L) Pr ote in( ml) (g!L)
SaUne 45 1513 ~~7 , ~~: 15 l · 1 260 13 00 17 2 .77
89 712 4 1 10 7 16 0".83
4 0 1529 98 289 lB 2.o i
4 5 1355 8 1 222 17 0 . 36
.
Dose To t a l Osm"ola lity Na K LD Total
( rng/k g ) Vo lume (U nit) ( mmol / L) (U / t. ) Pro1;e ln . ~(m l) (g/L)
6 20 ~450\\ .17 4 44 8 " 4 2. 837 30 44 25 >' 21 1.42
B 40 1188 41 20 1 16 1.30 f9 30 1753 . . . 92 30 4 29 3 .94





Ta b le 5 . Ur i n e Ch e mistr i e s Following Treratment wi th 6 m9.~kg
Doxorubicin Ve r s us S a l i ne Gr o up i n Twenty- Four<Hour' Urj.n e
.' Output . •
.'
Table 6. Urine Ch emistries Following Tr ea tment ~ith 9 mg/kg
Doxorubici n. No te . t h e decreased urine o u t pu t i n t h i s group
, ,
vers u s the s a l i ne treated g r ou p .
I,
....
;..~ . . . :''''
1 20
Dose Tota l Osmolality Na K LD Total
(mg!kg) Vol ume ' ( Unit) (mmo l!L) (U!L) Pr ote i n




1 2 19 71 4 . 54 125 1 0 . 63
13 17 1 644 12 8 32 0 1 2 0 .60
1 4 8 2268 11 7 32 9 14 1.35
1 5
>
3 3009 1 2 2 53 4 39 0 . 66
bose TO;;'1 Osmolality
(mg /kg ) y~~~me (Unit)
Na K LD Tota l '












15 4 380 32
82 220 13
124 366 28











Table 7 . Chemstrip.9 Dipstick' Screen Test on 24 Hour Uri ne
Specimens Fo llowing. Sal i ne Treatment. ~everal rats
demonst rated glycosuria .
.Table 8. Chemstrip 9 Dipstick Screen .Te st on 24 Hour Urine
Specimens ' F~l lowlng Tr e a t me nt with 3 mg/ kg noaorub i cr.n .
There was no difference be tween t~e saline, and 3 mg/kg
treated groul?s . Severa l rats demonstrated glycosuria .
."
1 2 2
Dose ( mg / kg )
S a line Sal i ne Saline Sa l i n e S a l i ne
Le uko c y t e s .
Nitri t e . .
pH 7 7 6 . B B
Pr ote i n 100 10 0 30 - 100 100 100 :
. ~~~~~:: 1 / 2 nor~a~ no rma l 1 /2 1 /4
Urobilin~en norma ~ no rmal ' normal no r-mat normal
Bilirubi n .
Blood 50 10 -50 10 10 ·50
Le ukocy t e s : l e uko . /ul Ketones : -/+
Ni t. r i te : ':'/ + Bilirubin:- - / +'
i'>rotei n : mg/d l Bl ood: erv , / u l
Glucose : g/d l
_ _ _ _ __--'--~--cc'- -- :
Dos e (mg / kg -)
' . ' .-'-...."~;- \';t'
--' ''-~
,.- -~
10 .". 10 25 0





























J,.eukocytes : l e uko . / u l
Ni t r ite : - / +
Pr otein: mg / d l
Gluc o s e : g jdl
Ketones : - j+
Bilir ubin : - /+
Bl ood : ery . jul
,,}
r',
...... . ;. ,
123 .
. :' .... ,: (
.... ) . '
) "
\.
,"" 0 00 • • _c<,,' "_",, ~'\,.", on ,:-_J.
( Spec i mens Following Tr e atment with 9 mg / kg Doxorubicip .
\ Ther~ was n o differenc e between t h e 6 . mg/kg and 9 mg/kg and
sa l l Ae ~eated g r oups. As 1n t he o the r 3 groups sev.e ra l





> ~.:. \~ b l ; 9 . Chemstrip VDipstick Scre~Test a n 2 4 Hou r Ur ine
-:' , ': ' ,~eJrmer.s, Following ~re. ;~e~t ~ith , mglkg Doxorubici n, »:






Leuk o cyt e s - 500 10 - 2 5 ~O-~ 10- 2 5Nit-,:-ite ; ' ~ 9 6~~oteln ~~~~ i~~o 30 100 100 'Gl ucose 1/ 20 1 /20 1/ ,20 t
) ~~~~~~~nogen no rmal normal normal no~l normal
Bilirubin
Blood 1Q.... 10 10 10- 50
t.euxccvtee r J.eu ko . jul
Ni t rite : - /+
'pro t e i !): mg/ dl
Glucose: o/dl
Ke t ona s : -/+
8iU¥Ub'in : - / +
























10 10 1 0
1 0 - 25
9
10 0
, 1 / 20
no r ma,!
Leukocytes : l eu ko . /ul
Nit~i te : - I i' '"
Prot e i n: ' mg /dl
Gl uco se : g / d l
J.'1;'
\.










Table 11 : Tota l CK ~ctiVi ty FO~ l Owlng Saline Trea'ttent .
There was .a fluc:uat~ ·1.n CK to~al act1v~ty . Das hed ' l i nes
indi cate t i mes when b lood was not co l lected.
"?" 12 . ree e i CK A c tiv i t y Fo l lowing 10 mf/ k9 Doxo~ubi c in .
• Again .n o t e the fluc t uation 1n CK tota~ ac.~1VitY . Das he d




"To t al CK Activity (U /L)
Hour s Post treatment
,
\ 2 4 4 8
,.
611 1019 410
28 5 49 2 48 459
15 29 2100 1240 7 42
531 581 530
335 343 413 417 . 299
2065 ", 2000 163 1 966 578




558 16170 9 156 11250 1380 '
171 330 1860 12160 40aO 2120
46 3 661 142~ - 95703 ' 4 455 2550555 86 20
\
>,.
, ', J' ,'.







Table 1 3. ,Serum Myoglob .1n Ass a y FOl lowing Saline Trllatment .
M~oglobln was not.. detec"ted 1n the serum a t ~ither 0 ' o r 4 8
h ours .
Table 14 . Serum Myoglobin Ass ay Fol lowing Tr e a t mE;lnt with
io mg/ kg Doxorubicin. My o g l ob i n ;-;oas detected at 4a" hou r s
p os t tre a t men.±. A pos t t 1 ve tes.t r es ul t lnd icate~ a minimum "
I



















Figur e ~2. SerulIl CK-MB AC~lV l~Y ( ll of t otal CK ) Following
Salin e Trea tment. The r e vee n o i nc r e as e 1n activity r r-oe 0
t o 48 hours posttreatment.
.\
· ~ / . ..
134








Fl,gure 33 . Se r um CK- MB Act,ivi ty (% Of tc ta l CK) Fo llowi ng
, Tfeatment wittylO mg/kg Doxo r ub i c i n . At 4 8 ' hou r s
posttreatment CK- MB a c tivity was> 5% of J,1Qtal CK act i vi t y ;
~ .
136
CK- MB Activi ty (% of Total CK)
~ - ~ - - N ~ ~ ~


















Various invasive a nd n on i n va s i ve t echh..tqUeS h a v e b~en used
t o assess cardiac function i n patients receiv i ng
DOKorubicin che mothe r apy . Unfortunatel y no 00 9 - te s t 1s
reliable , in the cl1n;lc:a1 setting, in p r e d i ct i ng which
p a ti e nt$ will develop cardiotoxiclty.
Electrocardiogl"sphic mon! taring 0; the patient is es!entia l.
fo l lowing myo c a rd i a l infarction, however i t ~hould n o t an d
1s n o t u s e d as a predictive tOOL bec au s e al t e rat ions
ind~icative of myo c a r d ial d a mag e f reque n t l y do - not appe ar ,.......:...,
prior t o t hei r clinica l pre s en tation . s u~ained elevation
of s ystolic time i ntervals h a v e b e e n suggested a s ' an
indicator: of cardiac d amag e , however t here 1s ~ high
incidence of false-posit ive a nd to a l esser e xtent f al s e -
'negat1 v~ r e s ':ll ts ~i th t his t e s t . Ra~iOnUCl1de angiogra~hY
provides assessment o f vent riCUl a r funct ion and has ~een
reported to be a usefu l marker of precl i nical toxicity
(Ritchie et al., 1960 ). Among the goals o f echocardiog r ap h y
a re to record abno rmal move ments of ~diac structures and
t.he~ de t e r mi nation of cardi a c dimens i~n . This techn ique ha s
shawn some promi se in predicting c ard eo d i sorde r s in
'" . .
patients t reat ed with Doxorubicin . Th~e hi s t o l ogic grade ' o f
the biop s y taken from the ri-g h t ve n t r i cle vi a t r an s v en ous
endomyo c a r d la l bio psy 1s usu ally a good c orrelat e with
cumul ative d r ug dose, however i t s p J;ed i ctive value i s in
ques tion ( Ritch ie e t a ~ .• 198 0 ).
13 9
4.1 . New Zealand White Rabbit Study
4 .1 .1 . T~tal CK and CK-M~. Me asur ement
There wa s a wide distributi on of tot a l CK act ivity 1 n t he
cont rol anq.. eXP1imental an i ma l s , further to .
i n t r a p e r i t o n e a l inj ection. o f saline and DOJi;orubicin
respectively . This likely represents s t r e s s -rela t e d release
of CK (MM component) from skeletal '!!uscle associated wi th
the b lood ' c o l l e c t i o n p r o c e s s. A follow up of t o tal CK
abtivity up t o 4 8 hou~emonstrated that 1n t he s a l i ne
tre~ted 'cc nc r o r group the en zyme ,jictiVltY returned t o more
mod erate levels, where as i n the d~ug tre a t ed a nima ls t h e
, I
enzyme a c t ivity rose s harJ11y and in·.~ost a n i ,na ls t e nde d t o
stay e l evated . I n v iew o f t he wide a n d vari a b le 0 ho ur
v a lue s fi rm c on c ruea c ne a re di f f iCUlt t o draw . Ye t , t he
overall pr ofil e s uggests tis su e r e l e as e cd CK spec i fic t o
d r ug tax i cl ty .
I n the e xperi ment al group , at 48 - hours .CK - MB was
c o nsis t e ntly above 5% of t otal CK ac tiv i t y L ve , CK -M B
Po s i t ive, as comp ared t o t he co ntrol g r ou p where i t wa s
consis tently negative. This f indino there fo re s ug gests more
s pec i f ic damage to myocard ia l t i ssue due to drug toxicity .
Heri (Heri et al . • 197 9 ) investig ated t he val u e of serum
CK - MB measurements a s a diagnostic t ool in mon t taring
'40
cardiac status fa llowing ant hracycllne therapy . the
\ s ub j ects in this study we re 4 2 patient s tre ated with e ithe r
Doxoru b icin or Daunorubl cln. Se rum CK- MB activity was
.. as sayed prior to and 15 hours pos ttreatment . At 0 hou r CI<-
MB act~ty wa s 4 .10 1. 2 .70 U/ L ( me an .± S.D.) versus 1 2 . 57
1. 7 .61 U! L at 15 ho urs . Cr eati ne kinase -MB activity in 7 o f
42 p i' '.:ients i ndicat ed cardiac abnor ma l ity. i n the a bs e nce o f
a t tet-atnons 1 n card'lac func t ion . Furt her cont.ror r ed
' .' . ....,
c U n i c al s t u d i e s with hu man s will haV? "to be cO~'1ducted to
determi ne the r ellabi l1 ty of s e r ia l meas~rements ~ CK-MB
r 'a c t i v irr,t y as a ' p redictive -tool f o r t hose pat i e nts wh o wi ll ,~ ;-
s ubsequently de v elop Doxoz:ub ic i n-ln duced car d iotoxic i t y . )
\
Thou gh e leva ted CK t cit 'al a c tivity c o u l d ar ise""from e i t he r
skeleta l muscle or\ardi8c mus cle ( t h e two tissue s ystems'
wi t h the high ? s t concentration o f the en z yme ) , CK- MB if
. released from s ke leta l musc le a l on e wou l d at no t ime
cons t i tute more tha Q 3 to 5% of tota l CK a c tivi ty .
4 .1 .2. LD Total and I s oenzyme Analysis
', A. fair number of blood s amp les from t he r a bbi ts e xh i b i t e d
mi n im um t o moderate h e molysis . Thi s wa s s o i n s p i t e o f
ind~.·e lling bu tter f l y c annulae in the ear v e i ns and slow
a s piration . ,As he mol ys is i nter:!e r e l:!. wi t h both t o t a l and





would prove fut ile i n demonstratio n of myocardial d ama ge
due to Doxorubicin toxicity .
4 .1.3 . Myoglobin As say
Myoglobi n was det:ected in the serum of all rabbits 48 hour s
s u bsequent to Doxorubicin admi nistr ation , but not ~ n '1;he
. .
saline treated eorrta-ca s , Since myog lobin has the grea t es t
activity i .sithe ~YOCBrdium and skel e tal muscle i t could
have been r e l eased from e i th.,;-r of th.ese sources .
Th e purpose of the stu dy with t he rabbit model was a n '
attempt to identi fy ma~kers o f Doxorubicin cardiotoxicity .
The signif~cant serum CK-MB act!.v ity f Ol 'l o wi ng Doxorubicin
treatment i n'di cated myocardia l damag e . If t his t e c hn iqu e
does prove fru! tfu l i t ....ould be an easy . pa inless me t ho d o f
moni toring patients during Do xoru b i c i n treatment . Al though
.. .
myog lobi n was present i n t he serum s ubsequent t o q.rug
t r e a t me n t , for now i~ cannot be advocated as a marke r of
myo c l;lr dia l da~age b e c au s e its tissue ' o r i g i n was not fur t h er
explored.
There were difficu l t ies ex perienced wi'th the New Ze a l an d
White rabbit mode l ' i?' b l OOd co l lect ion. Also , t here was one
de a th in t he ' e xperimontal g roup . An a u t o ps y r e v e a l ed s e v ere
pe r itone al a nd p l eural e f f us i ons whi c h were a lso obsetved
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to a les s er degree at the time of s acrific e 1n all rabbits
t r e ated wi th the drug . 'rnece r os-e we proceeded to study
Do xo r ub i cin- a s s o c i a t e d t oxicity in the Sp rague -Daw ley r a t
mode l .
40.2. Sprague-Dawley Rat Study
The inve s t igation with this model i nvolved t h e s tud y of
b i o chem i cal pa rameter s i n serum a nd urine t o detect acute
toxicl:ty of the drug on org s ,!. ~x~tems . specifically t~e
I).eart . liver' and kidney . The tissue con centir-abf.cna of the
drug were measu r e d i n the myoc .ardium and cbrrelated w1th
t he degree o f toxicity reflected ~Y the t i ssue.
4 . 2. 1. Tota~ Enzyme Activity Analysis
With a dministrat i on o f the 3 and 6 mg/kg do se s of
Doxor ub ici n there wa s a s igni f i cant i nc reas e in ser u m CK
activity a t 48 hours ,,"s .c omp a r e d t o a ~r...uc , On _ th~ other .
hand , t t:!:e rat s treated with 9 mg/kg of ~he drug s ho we d a
s i g ni fica n t decrease at 46 hours . The contrt>l group s ho wed
"a m.oderat e decr~ase in CK ac tivity a t 48 hours compared to
o ho ur. thOtt9h the values were n ot; significantly different
.. f r:om eac h other. Cardioto xi ci 'ty a s sociated with Doxorubi cin
us e has eeeo, demonst rated in .th e rat / rabbit /human model.
There f ore we can suggest . that the t otal OK act iVity
i nCr e a £!s s observed with 3 mg/kg and 6 mg/kg ~oseB
"
I143
represent r elease o f enzyme d ue to c a r diotoxi c ! t y. The
d ecr ease i n CI< &ettVi tY with the 9 ~9/k9 dose may be
,
r e l a t e d to decreased protelnsynthesls . Howe v er , we were
unable to d e monst r a t e any B ignific~t d i f fere nc e be tw e e n
myocardial tl~sue a ctivity a f CK between 9 mg/ kg
lJoxorubi cin treated and co ntrol animal s .
J
Ther-e was a significant · increase in serum LD activity a t 4 8
ho urs' i n t he rats t reated ~i t h , 6 andl"Jl mg/kg Doxor1fbicin
when compared to the control s. However in the an ima ls
treated with t he 3 fig /kg dose of t he drug the loera.aae w~s
not . statistical ly s ignificant . It i s r easonable to
postulate .t l)a t the i nc r e a s ed sezum LD ac t i v i,t y was
p r e dom inant ly of myocardial o r i g i n be cause of its high
a c tivity in c ardiac t i s s u e and the k nown n e gat ive effect o f
the drug on t his tissue. However it is conceivable that it \
c ou 1 d have been rel~ased froin other o r g a n s ystems because
of its ubiquitous tissue distribution .
Sim i1a r to LD ac t ivity. serum AST act ivity increase.d
s ubsequent t o tre a t me n t wi t h the 3 doses of Doxorubic i n .
Statistical ana lysis indicated significant d ifferences
between t he means of t h e contro1 and 3 mg/kg group a nd
between the contro1 a nd 6 mg/kg group 'Ot 48 hours . ThE!
h e ar t an d 1 iver are t h e 2 tissues with high AST actiV i ty .
I t i s not p o s sible to e xp1aln the increased serum PoST
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activity fol lowing drug t reatment as being exclusively
de r i v e d from cardi a c ti s sue alone o r hepati c tissue a lone .
s i g ni f ica n t 'd if f e r e n c e i n activity between treatment wi t h
A signi f icant incr ease 1n ser u m ALT activi ty was ' noted a t
\~.~ 48 hours in tho 9 mg/kg treated an imals only . NoI
s a li ne and t he drug was demonstrtated at 48 hours i n all
other groups : Th e liver and k idney are the two t i ssues .w~th
significant ALT activity 9uggest ing its r e i e a s e :t,nto .t h e
se rum from a1 ther or both of thes~ lources. seru~ alkal~ne
pho sphatase act i v ity was very l o w (0-5 U/L) and not
affect.ed by drug. treatment however this i s a bi liary tree
enzyme whereas ALT 19- a he p at oc e l l u l a r enzyme and
therefor~ ALT wou ld be more s ens i t i ve to ear\y
hepatoce l l ula r damage. There was no demonstrable ev idence
o f renal damage (see Urinalysis) and in conjuno't Ion with
t h e results of LD i s o enzyme analysis ( see 4 . 2 . 4 . ) we
po stulate liver tiss ue as the source of i ncreased ALT
activity foll owi ng the 9 ,mg/kg do se .
; .J
4 . 2 . 2 . Creatine Kinase I soenzyme Analys i s
The- CK i soenzyme pa ttern o f s a l i ne treated controls and
Doxorubicin treated an imals de monstrated th~ 3 more
oommcn Ly known "cy t o s o l i c " isoenzymes CK~MM. CK- MB sn d




Laoenayme while the o t her !wo we re pre s ent 1n variable
"p e z-c e ntieqe s in t h e i ndivid ual a n ,lmals . However there wa s no
noticeable dif ference in t h e serum CK isoenzyme pattern by
elec tro ph oresi s "betwe e n t he ex pe r imenta l an d c o ntro l
grou p s .
Se r um CK isoen z yme ~ana lysl s r e v e e red the pr e senc e of a
fou r th band 'fol lowi n g treat~t with 6 an d 9 mg/kg
. Dmco r f>iCi n . Ba sed o n inf orma tion av ail ahle i n humans, t his
fourth cathod ically m~grating b and was c on s tdered to be
po s sibly of mi tochondrial o rigi n. Furthel: exporlme~tatlon
wa s c ar r i e d out t o con fi r m t his .
~ , '), ,4[.3.~~I'"CI odrle l Isolation
T determ ine the natu r e o f "t hi s f ou r th ba nd, mi tochondria
we e i solated i n ti s sue from un tre ated r at s a n d analyzed as
• 0
to I ts CK isos nzy'tbe pattern . Two _bands were pz-eaenb , One
corl1e sp onded to CK- MM Of l the stand ards an d was be j Leved to '
or igi na t e f r om lyso zy mes (refer to pag e 112 ). The pr oced ure
followed f or mi t och ondrial i solation did not yie ld
esciue av erv mi t oc hondria , but rather the re was some
't"~zyma l contami nation . Th e second band at a ,.point
cathopal t o CK- MM corresp onded i n position t o the f ourth
band ' s ee n with the Doxorubicin treated ani mals , s ugg es t i ng
that t he latter might be of nu t ocbon drr a t origin ( refer tel\,
y
/page 11 2 ). We believ a that with d o ses o f 6 and 9 mg/kg
t he re was damage to the mitoch ondria re stJlt l'hg io 'the
r e l e ase of mitoc hondrial CK.
4 . 2 .4 . LD :rsoenzymeAnalysls
I '
.-- Endothelial cel l damage mal ' po s sibly a ccount f or the
eleva t i on o f LO-3 s erum activi t y in the.. present study with
the 9 .mg/kg dose -. The increased LO- 4 anVL~~; act~~ltY
f ollowing treatment with the 9 mg/kg dose, sug ges ted damage ( .
to liv er a nd/ or skeletal mus cle : If the LD- 4 B:n d LO- 5 -
. r: ">: .o~ lginated from s ke l etai mus c le , tt- ~s would have be en -
a SSOf i ated wi tfi the r e l e ase o f CK-MM end inc reased s e r um
activity o f t ot a l CK wh i le 1n e ffect t her e wa s a l owered
ac t i v ity with> 9 mg/kg . 'rtie r e rcre the live r was the possible
source 0'£ L D- 4 e e e.uo-s which was supported by e levat i on o f
ser um ALT activity wi t h the 9 mg / kg dose : Ol son ·( Olson and
Sh a n n on , 19 79 ) quantitativel.y analyzed the LD i soenzymes
s u b s e q ue n t tic-on e do s e o f 20 mg/kg .Doxorubicin, i .p ., i n
I
f e male COF rat s . They obseted an increase in serum LO- l .
and LO-2 activity a s ear1~as 12 hour s , with peak act'ivity
a s 48 hours . I n ou r stud y we no t e d an increase i n L~-l and
LD-2 a ctivity wi th i n cre asing drug dose . Thi s i s ~nother
i ndicatio n of myocar di a l da ma g e because t"'e heart has the
'highest t i s s ue a ctivitie s o f th7 an odic t o r eoeneveee ,
:-."
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4 . 2 . 5 . . Urinalysis
,
Urine analysis was the method u s e d t o de tect s i g n s of
n e p h r o t o x i c! ty because t h e coinp~si t i c n o f t he urine is
l a r g ely "de pende nt o n the fu nc t i o n and integrity of r enal
. " • --..I
t i s sue . The uri ne wa s e x a mi ned as to Volume, p H-..
. .
elec ,t r oly te c ompoe.t tn.on.. t o t al p r o t ein end various
biochemical pararne t'ers ' r eferred t o i n- t he r e s u l t s .
Th e Che mstr'ip 9 Dips t i c k Screel). . de mo n s t r a t e d n o
abnormalities i n any o f the groups exce pt for .t he presenc e
of glyco s uria ~hlch wa s believed t o 'b e due t o str ess. Ther~
. was no c hange in "t he . 24 hou r urine tot al p;rotein o utP]Jt
be t ween ,t he c on trol a nd the 3 e 'xperimental g r o u ps . This
s ug g,:s t e d t h? ?gni ~icant glomer u la r . d ama g e wa s u n l i k e ly
in the drug ~ated g rou ps , a s p r o t eJ. n output i s a marl<er
o f glomeru:"ar (a nd to a I sar e x t ant t~bu l a r) integr i ty .
Th ere wa s 8 r e duce d 24 our urini'VO I u me observed wi t h t he
drug t r eated anima.l s s. comp a red t o the ~ontrols , t h o ug h
'" this finding was n o universal . -
" " to •
"---_. \
4. 2. 6. Drug Me a s ure me n t
Wit h' increasin g dose administe red by i .p , i nj ect ron t her e
was increasing "!?ar ent drug l eve l~ in t h e -myoca r d i um. The
measurement of Acfr i a myc ino l , th~ primary metabol1 te C;; f
\
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Doxor u bicin thought to be cytotoxic was Important 111 t hese
tissues y e t measurement o f the ~etaboli tea was not
po ssible be cause standards were n~ ava ilable for
identification o f the various pe aks.\b ~
4 . 2 .7 . Concl us ion
/-
By a n a l y z i ng t h e ser um activity of enzymes ,s pe c i f i c f o r
c a r d i ac t i s s u e (CK·, CK-MB. LD, and1.0 lS0enz~es,
spec i fically LD-~ and LO- 2 ) we have demonstrated
Doxorubicin-induced ca<rdiotoxlclty . 1:re atment " wl~6 and 9
. ' . '
mg/ k g Doxorubicin produced roi t o c ho n dr i 'a l damage as
evidenced by t h e app~arance of mf t ochondrial CK in t h e
serum o f t hese rats. Following ...trea t men t with 9 mgjkg there
was in add! ticn ~epatlc damage as, evidenced by increased
serum ALT and ~-4 and LD-5 a c t i v i t i e s . urine ..ana}ysis did
not reveal any rena l damage as t he r e was n e;; major
differen?e between the control and experimenta l groups ,
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